Francesco Nappi

Dr. Francesco Nappi

Consultan Cardiac Surgery
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in JACC
Verified
Journal Article
Closed access
FNFrancesco Nappi
Francesco Nappi
MLMario Lusini
Mario Lusini
CSCristiano Spadaccio
Cristiano Spadaccio
ANAntonio Nenna
Antonio Nenna
ECElvio Covino
Elvio Covino
MCMassimo Chello
Massimo Chello

Verified
Journal Article
Open access
PDF file
FNFrancesco Nappi
Francesco Nappi
The use of non-coding RNAs (ncRNAs) as drug targets is being researched due to their discovery and their role in disease. Targeting ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), is an attractive approach for treating various diseases, such as cardiovascular disease and cancer. This seminar discusses the current status of ncRNAs as therapeutic targets in different pathological conditions. Regarding miRNA-based drugs, this approach has made significant progress in preclinical and clinical testing for cardiovascular diseases, where the limitations of conventional pharmacotherapy are evident. The challenges of miRNA-based drugs, including specificity, delivery, and tolerability, will be discussed. New approaches to improve their success will be explored. Furthermore, it extensively discusses the potential development of targeted therapies for cardiovascular disease. Finally, this document reports on the recent advances in identifying and characterizing microRNAs, manipulating them, and translating them into clinical applications. It also addresses the challenges and perspectives towards clinical application.

4 December 2019 in Recent Patents on Inflammation & Allergy Drug Discovery
Verified
Journal Article
Open access
PDF file
OGOmar Giacinto
Omar Giacinto
USUmberto Satriano
Umberto Satriano
Antonio NennaAntonio Nenna
Antonio Nenna
Cristiano SpadaccioCristiano Spadaccio
Cristiano Spadaccio
MLMario Lusini
Mario Lusini
MCMassimo Chello
Massimo Chello
Background: Endothelial injury occurring during cardiopulmonary bypass is a major contributing factor in the development of organ dysfunction, which leads to many of the postoperative complications occurring during cardiac surgery. Objective: This narrative review aims to summarize the main mechanisms of cardiopulmonary bypass - related disease, evaluating the unfavorable events leading to tissue injury, with a description of current pharmacologic and non-pharmacologic mechanisms to reduce CPB-related injury. Methods: A Medline/Pubmed/Scopus search was conducted using clinical queries with the key terms "cardiac surgery", “cardiopulmonary bypass”, "inflammation" and “endothelial injury”, and related MeSH terms, until July 2019. The search strategy included meta-analyses, randomized controlled trials, clinical trials, reviews and pertinent references. Patents were searched using the same key terms from https://patents.google.com/, www.uspto.gov, and www.freepatentsonline.com. Results: In this review, we discuss the current knowledge of the mechanisms of vascular endothelial cell injury, the acute inflammatory response, and the regulatory factors that control the extent of vascular injury during extracorporeal circulation, summarizing the main target of anti-inflammatory pharmacologic and non-pharmacologic strategies. Conclusion: Inflammatory response and endothelial dysfunction following cardiopulmonary bypass are the prices to pay for the benefits offered during cardiac surgery procedures. Counteracting the detrimental effect of extracorporeal circulation appears to be crucial to improve clinical outcomes in pediatric and adult cardiac surgery. The intrinsic complexity and the tight interplay of the factors involved might require a holistic approach against inflammation and endothelial response.

8 March 2022 in Life
Verified
Journal Article
Open access
PDF file
ANAnnunziata Nusca
Annunziata Nusca
MVMichele Mattia Viscusi
Michele Mattia Viscusi
FPFrancesco Piccirillo
Francesco Piccirillo
AFAurelio De Filippis
Aurelio De Filippis
Antonio NennaAntonio Nenna
Antonio Nenna
GUGian Paolo Ussia
Gian Paolo Ussia
Despite the dramatic improvements of revascularization therapies occurring in the past decades, a relevant percentage of patients treated with percutaneous coronary intervention (PCI) still develops stent failure due to neo-atherosclerosis (NA). This histopathological phenomenon following stent implantation represents the substrate for late in-stent restenosis (ISR) and late stent thrombosis (ST), with a significant impact on patient’s long-term clinical outcomes. This appears even more remarkable in the setting of drug-eluting stent implantation, where the substantial delay in vascular healing because of the released anti-proliferative agents might increase the occurrence of this complication. Since the underlying pathophysiological mechanisms of NA diverge from native atherosclerosis and early ISR, intra-coronary imaging techniques are crucial for its early detection, providing a proper in vivo assessment of both neo-intimal plaque composition and peri-strut structures. Furthermore, different strategies for NA prevention and treatment have been proposed, including tailored pharmacological therapies as well as specific invasive tools. Considering the increasing population undergoing PCI with drug-eluting stents (DES), this review aims to provide an updated overview of the most recent evidence regarding NA, discussing pathophysiology, contemporary intravascular imaging techniques, and well-established and experimental invasive and pharmacological treatment strategies.

25 July 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
FNFrancesco Nappi
Francesco Nappi
GMGiorgia Martuscelli
Giorgia Martuscelli
FBFrancesca Bellomo
Francesca Bellomo
SSSanjeet Singh Avtaar Singh
Sanjeet Singh Avtaar Singh
MMMarc R. Moon
Marc R. Moon
Infective endocarditis remains an illness that carries a significant burden to healthcare resources. In recent times, there has been a shift from Streptococcus sp. to Staphylococcus sp. as the primary organism of interest. This has significant consequences, given the virulence of Staphylococcus and its propensity to form a biofilm, rendering non-surgical therapy ineffective. In addition, antibiotic resistance has affected treatment of this organism. The cohorts at most risk for Staphylococcal endocarditis are elderly patients with multiple comorbidities. The innovation of transcatheter technologies alongside other cardiac interventions such as implantable devices has contributed to the increased risk attributable to this cohort. We examined the pathophysiology of infective endocarditis carefully. Inter alia, the determinants of Staphylococcus aureus virulence, interaction with host immunity, as well as the discovery and emergence of a potential vaccine, were investigated. Furthermore, the potential role of prophylactic antibiotics during dental procedures was also evaluated. As rates of transcatheter device implantation increase, endocarditis is expected to increase, especially in this high-risk group. A high level of suspicion is needed alongside early initiation of therapy and referral to the heart team to improve outcomes.

1 February 2017 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
FNFrancesco Nappi
Francesco Nappi
CSCristiano Spadaccio
Cristiano Spadaccio
ANAntonio Nenna
Antonio Nenna
MLMario Lusini
Mario Lusini
MFMassimiliano Fraldi
Massimiliano Fraldi
MCMassimo Chello
Massimo Chello